Navigation Links
Doctors Test Advanced Tool for Treating Prostate Cancer
Date:10/27/2008

Technology Designed to Confirm Precise Brachytherapy Treatment

ST. LOUIS, Oct. 27 /PRNewswire/ -- Leading radiation oncologists are using the TargetScan Touch(TM) system to deliver radioactive seed therapy in the prostate. The innovative technology is based on a motionless probe which stabilizes the prostate during procedures. With the gland stabilized, physicians use a touch-screen interface and 3-D ultrasound images to map and confirm placement of radiation.

Unveiled recently at the 2008 American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting, the TargetScan Touch(TM) has been tested at several of the nation's leading medical centers, including Emory University School of Medicine.

"This technology delivers two important benefits. First, a stabilized prostate; second, the ability to quickly and efficiently image anywhere in the prostate with the point and click function for accurate positioning of radioactivity," explains Peter Rossi, M.D., Emory's assistant professor in the departments of radiation oncology and urology. "TargetScan has a short learning curve for my residents and physicists and has demonstrated its value in that we have consistently achieved quality implants with its help."

Just launched, the system will initially be in clinical use at Emory, Washington University Medical Center in St. Louis, University of Florida and New Hanover Radiation Oncology.

The system is based on the TargetScan(R) technology platform developed by Envisioneering Medical Technologies in St. Louis, under the guidance of physicians at Washington University. "Traditional hand-manipulated devices allow the prostate gland to shift, which impedes placement accuracy. By stabilizing the prostate, physicians can now implant seeds to any and every region of the gland with greater confidence," said Robert Mills, president, Envisioneering Medical Technologies.

Other system features include intuitive imaging and navigational controls and a compact, streamlined system design to enhance treatment efficiency, improve the patient experience and provide ease of transport for physicians managing multiple practice locations.

"The design of TargetScan Touch(TM) is straightforward to support ease of use and widespread adoption so that physicians and their patients can benefit from this new technology," added Mills. "The simplicity of the touch-screen technology saves time while producing detailed images and treatment reports for future patient monitoring."

TargetScan Touch Technical Features:

-- Motionless probe to prevent prostate movement and on-screen image distortion.

-- Mapping technology for complete prostatic coverage, assisting with accurate needle placement to pre-planned cancer targets and preferred treatment zones.

-- 3-D image acquisition to improve visibility, presenting both sagittal and transverse planes with a total viewing volume of 380 mL.

-- Touch-screen technology to improve treatment efficiency and patient experience.

About Envisioneering Medical Technologies

Envisioneering Medical Technologies, based in St. Louis, Mo., is dedicated to creating the standard for prostate cancer care by developing technology for improving prostate cancer diagnosis and treatment precision and effectively managing patients throughout the continuum of care. For more information please visit http://www.envisioneeringmedical.com.


'/>"/>
SOURCE Envisioneering Medical Technologies
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Doctors Company Launches Litigation Education Retreats to Assist Physicians Involved in Medical Litigation
2. Doctors Lack Smoking Cessation Training
3. Doctors Often Overestimate Patients Health Literacy
4. MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource
5. Research suggests doctors should consider kidney-sparing surgery
6. Will patients stick to physical therapy? Questionnaire can help doctors predict
7. Help for Stutterers on The Doctors TV Show Presented by Power Stuttering Center Founder Mark Power
8. Maternity Care Doctors to Call for Renewal of MCARE Abatement Fund, Address Growing Shortage of Maternity Care Physicians
9. For Some Doctors, Empathy Is in Short Supply
10. Many Doctors Dont Know Blood Pressure Guidelines
11. UC Davis doctors use multimedia to increase colorectal cancer screening among Hispanics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... ... “Letters From Home”: a moving compilation of letters that remind readers of ... Home” is the creation of published author, John Allred, a passionate leader of ministry ... International, who has traveled and ministered on four continents. , “It is my hope ...
(Date:9/21/2017)... CA (PRWEB) , ... September 21, 2017 , ... With ... so fun and easy to do. Users can select from up to two layers ... with a click of a mouse all within Final Cut Pro X. ...
(Date:9/21/2017)... ... September 21, 2017 , ... The American Addiction Treatment ... for professionals in the addiction treatment industry entitled: Special Investigations Unit (SIU) ... companies and state and federal governments are increasingly scrutinizing the addiction treatment industry ...
(Date:9/21/2017)... ... ... Bill Howe Plumbing’s mission is to create an employee friendly company, provide ... over 37 years, they have operated with their mission at the foundation and have ... They were chosen as the Best San Diego plumber in 2016, named a Top ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... developing low-cost and highly accurate cancer screening tests, has received two prestigious recognitions ... in cancer survival rates. , Preora has been named a Top ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
(Date:9/9/2017)... , Sept. 9, 2017  Eli Lilly and ... primary and secondary endpoint data for lasmiditan, an investigational, ... which demonstrated statistically significant improvements compared to placebo in ... highlighted today at the 18th Congress of the International ... "The data presented today demonstrate lasmiditan,s potential ...
(Date:9/7/2017)... WARSAW, Ind. , Sept. 7, 2017  Zimmer ... leader in musculoskeletal healthcare, today announced that it will ... Annual Global Healthcare Conference at the Grand Hyatt hotel ... September 11, 2017 at 11:40 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
Breaking Medicine Technology: